Spectrum Vascular develops and provides advanced vascular access devices designed to improve medication delivery and patient outcomes. Their products focus on enhancing the safety and efficacy of intravenous therapies while reducing complications associated with vascular access.
Funding
Funding not disclosed
Founders
Product
Problem
Vascular access complications, such as catheter-related bloodstream infections (CRBSIs) and thrombus accumulation, pose significant risks to patients requiring intravenous therapies. These complications can lead to increased healthcare costs, longer hospital stays, and reduced patient satisfaction.
Solution
Spectrum Vascular provides a portfolio of vascular access devices designed to mitigate common and costly complications. Their SV Spectrum™ catheters utilize minocycline and rifampin impregnation to provide antimicrobial protection against CLABSIs and CRBSIs. The SV BioFlo catheters incorporate Endexo® technology, a surface-modifying macromolecule, to reduce thrombus accumulation and related catheter complications. By offering solutions focused on infection prevention and thrombus reduction, Spectrum Vascular aims to improve patient outcomes and reduce the economic burden associated with vascular access procedures.
Target Audience
Spectrum Vascular's products are intended for use by healthcare providers, including physicians, nurses, and other clinicians, in hospitals, clinics, and other healthcare settings.
Features
- SV Spectrum™ CVCs, impregnated with minocycline and rifampin, provide antimicrobial protection against CLABSI and CRBSI.
- SV BioFlo PICCs and Midlines incorporate Endexo® technology to reduce thrombus accumulation.
- SV BioFlo PICCs are available with PASV Valve Technology to automatically resist backflow and reduce blood reflux.
- Comprehensive range of vascular access devices, including CVCs, PICCs, Midlines, IO Needles and Arterial Catheters.
- Products available in a variety of sizes and design configurations to suit individual patient needs.